These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 33626220

  • 1. Complete metabolic response with [18 F]fluorodeoxyglucose-positron emission tomography/computed tomography predicts survival following induction chemotherapy and radical cystectomy in clinically lymph node positive bladder cancer.
    Abrahamsson J, Kollberg P, Almquist H, Bläckberg M, Brändstedt J, Lyttkens K, Simoulis A, Sjödahl G, Sörenby A, Trägårdh E, Liedberg F.
    BJU Int; 2022 Feb; 129(2):174-181. PubMed ID: 33626220
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer.
    Kollberg P, Almquist H, Bläckberg M, Cwikiel M, Gudjonsson S, Lyttkens K, Patschan O, Liedberg F.
    Scand J Urol; 2017 Aug; 51(4):308-313. PubMed ID: 28532260
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L, Capozza A, Bandini M, Raggi D, Farè E, Pederzoli F, Gallina A, Capitanio U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, Giannatempo P, Serafini G, Padovano B, Salonia A, Briganti A, Montorsi F, Alessi A, Necchi A.
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Added Clinical Value of 18F-FDG-PET/CT to Stage Patients With High-Risk Non-Muscle Invasive Bladder Cancer Before Radical Cystectomy.
    van Ginkel N, van Gennep EJ, Oosterbaan L, Greidanus J, Boellaard TN, Wondergem M, Vis AN, de Reijke TM, van Rhijn BWG, Mertens LS.
    Clin Genitourin Cancer; 2023 Jun; 21(3):342-348. PubMed ID: 36918302
    [Abstract] [Full Text] [Related]

  • 13. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
    Rouanne M, Girma A, Neuzillet Y, Vilain D, Radulescu C, Letang N, Yonneau L, Hervé JM, Botto H, Le Stanc E, Lebret T.
    Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
    [Abstract] [Full Text] [Related]

  • 14. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
    Goodfellow H, Viney Z, Hughes P, Rankin S, Rottenberg G, Hughes S, Evison F, Dasgupta P, O'Brien T, Khan MS.
    BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
    Swinnen G, Maes A, Pottel H, Vanneste A, Billiet I, Lesage K, Werbrouck P.
    Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.